pemetrexed (Q415220)

https://www.ismp.org/recommendations/tall-man-letters-list

(2R)-2-[[[4-[2-(2-amino-4-oxo-1,7-dihydropyrrolo[2,3-d]pyrimidin-5-yl)ethyl]phenyl]-oxomethyl]amino]pentanedioic acid

2 September 2022

stereoisomer of

1 reference

based on heuristic

inferred from InChI

chemical formula

C₂₀H₂₁N₅O₆

1 reference

Pemetrexed Fresenius Kabi

Alimta (English)

3 October 2016

C1=CC(=CC=C1CCC2=CNC3=C2C(=O)N=C(N3)N)C(=O)NC(CCC(=O)O)C(=O)O

0 references

isomeric SMILES

C1=CC(=CC=C1CCC2=CNC3=C2C(=O)N=C(N3)N)C(=O)N[C@@H](CCC(=O)O)C(=O)O

0 references

1 reference

14 February 2018

1 reference

EMEA/H/C/003895

http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/003895/human_med_001999.jsp

22 March 2017

Pemetrexed Hospira

1 reference

EMEA/H/C/003970

http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/003970/human_med_001936.jsp

22 March 2017

Pemetrexed Lilly

1 reference

EMEA/H/C/004114

http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/004114/human_med_001913.jsp

22 March 2017

Pemetrexed Medac

1 reference

EMEA/H/C/003905

http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/003905/human_med_001937.jsp

World Health Organisation international non-proprietary name

22 March 2017

pemetrexed (English)

1 reference

Pemetrexed (English)

medical condition treated

19 January 2016

benign pleural mesothelioma

1 reference

non-small-cell lung carcinoma

2 October 2018

1 reference

2 October 2018

benign mesothelioma

1 reference

2 October 2018

bronchus carcinoma

1 reference

malignant pleural mesothelioma

2 October 2018

start time

19 August 2004

approved by

United States Food and Drug Administration

1 reference

Inxight: Drugs Database

2 November 2018

https://drugs.ncats.io/drug/04Q9AIZ7NO

http://www.accessdata.fda.gov/drugsatfda_docs/label/2009/021462s021lbl.pdf

significant drug interaction

nabumetone

1 reference

A reference set of clinically relevant adverse drug-drug interactions

naproxen

1 reference

A reference set of clinically relevant adverse drug-drug interactions

celecoxib

1 reference

A reference set of clinically relevant adverse drug-drug interactions

Diclofenac

1 reference

A reference set of clinically relevant adverse drug-drug interactions

piroxicam

1 reference

A reference set of clinically relevant adverse drug-drug interactions

meloxicam

1 reference

A reference set of clinically relevant adverse drug-drug interactions

(RS)-fenoprofen

1 reference

A reference set of clinically relevant adverse drug-drug interactions

(±)-flurbiprofen

1 reference

A reference set of clinically relevant adverse drug-drug interactions

ibuprofen

1 reference

A reference set of clinically relevant adverse drug-drug interactions

indomethacin

1 reference

A reference set of clinically relevant adverse drug-drug interactions

(RS)-ketoprofen

1 reference

A reference set of clinically relevant adverse drug-drug interactions

(RS)-etodolac

1 reference

A reference set of clinically relevant adverse drug-drug interactions

sulindac

1 reference

A reference set of clinically relevant adverse drug-drug interactions

parecoxib

1 reference

A reference set of clinically relevant adverse drug-drug interactions

aceclofenac

1 reference

A reference set of clinically relevant adverse drug-drug interactions

tenoxicam

1 reference

A reference set of clinically relevant adverse drug-drug interactions

aspirin

1 reference

A reference set of clinically relevant adverse drug-drug interactions

aspirin

1 reference

A reference set of clinically relevant adverse drug-drug interactions

aspirin

1 reference

A reference set of clinically relevant adverse drug-drug interactions

nabumetone

1 reference

A reference set of clinically relevant adverse drug-drug interactions

nabumetone

1 reference

A reference set of clinically relevant adverse drug-drug interactions

naproxen

1 reference

A reference set of clinically relevant adverse drug-drug interactions

naproxen

1 reference

A reference set of clinically relevant adverse drug-drug interactions

celecoxib

1 reference

A reference set of clinically relevant adverse drug-drug interactions

celecoxib

1 reference

A reference set of clinically relevant adverse drug-drug interactions

Diclofenac

1 reference

A reference set of clinically relevant adverse drug-drug interactions

Diclofenac

1 reference

A reference set of clinically relevant adverse drug-drug interactions

piroxicam

1 reference

A reference set of clinically relevant adverse drug-drug interactions

piroxicam

1 reference

A reference set of clinically relevant adverse drug-drug interactions

meloxicam

1 reference

A reference set of clinically relevant adverse drug-drug interactions

meloxicam

1 reference

A reference set of clinically relevant adverse drug-drug interactions

(RS)-fenoprofen

1 reference

A reference set of clinically relevant adverse drug-drug interactions

(RS)-fenoprofen

1 reference

A reference set of clinically relevant adverse drug-drug interactions

(±)-flurbiprofen

1 reference

A reference set of clinically relevant adverse drug-drug interactions

(±)-flurbiprofen

1 reference

A reference set of clinically relevant adverse drug-drug interactions

ibuprofen

1 reference

A reference set of clinically relevant adverse drug-drug interactions

ibuprofen

1 reference

A reference set of clinically relevant adverse drug-drug interactions

indomethacin

1 reference

A reference set of clinically relevant adverse drug-drug interactions

indomethacin

1 reference

A reference set of clinically relevant adverse drug-drug interactions

(RS)-ketoprofen

1 reference

A reference set of clinically relevant adverse drug-drug interactions

(RS)-ketoprofen

1 reference

A reference set of clinically relevant adverse drug-drug interactions

(RS)-etodolac

1 reference

A reference set of clinically relevant adverse drug-drug interactions

(RS)-etodolac

1 reference

A reference set of clinically relevant adverse drug-drug interactions

sulindac

1 reference

A reference set of clinically relevant adverse drug-drug interactions

sulindac

1 reference

A reference set of clinically relevant adverse drug-drug interactions

parecoxib

1 reference

A reference set of clinically relevant adverse drug-drug interactions

parecoxib

1 reference

A reference set of clinically relevant adverse drug-drug interactions

aceclofenac

1 reference

A reference set of clinically relevant adverse drug-drug interactions

aceclofenac

1 reference

A reference set of clinically relevant adverse drug-drug interactions

tenoxicam

1 reference

A reference set of clinically relevant adverse drug-drug interactions

tenoxicam

1 reference

A reference set of clinically relevant adverse drug-drug interactions

physically interacts with

dihydrofolate reductase

enzyme inhibitor

1 reference

6837

Phosphoribosylglycinamide formyltransferase

17 August 2016

enzyme inhibitor

1 reference

6837

17 August 2016

Thymidylate synthetase

enzyme inhibitor

1 reference

6837

imported from Wikimedia project

17 August 2016

pregnancy category

US pregnancy category D

1 reference

English Wikipedia

LiverTox likelihood score

LiverTox toxicity likelihood category E*

1 reference

8 April 2021

https://www.ncbi.nlm.nih.gov/books/n/livertox/Pemetrexed

last update

18 April 2016

mass

427.149183 dalton

1 reference

United States Food and Drug Administration

Alimta (English)

3 October 2016

1 reference

http://www.asbestos.com/treatment/chemotherapy/alimta.php

protein synthesis inhibitor

1 reference

5 March 2018

1 reference

5 March 2018

1 reference

15 March 2018

1 reference

MeSH descriptor ID

D000068437

15 March 2018

folic acid antagonists

1 reference

MeSH descriptor ID

D000068437

DNA polymerase inhibitors

15 March 2018

1 reference

InChI=1S/C20H21N5O6/c21-20-24-16-15(18(29)25-20)12(9-22-16)6-3-10-1-4-11(5-2-10)17(28)23-13(19(30)31)7-8-14(26)27/h1-2,4-5,9,13H,3,6-8H2,(H,23,28)(H,26,27)(H,30,31)(H4,21,22,24,25,29)/t13-/m0/s1

15 March 2018

Pemetrexed

0 references

Identifiers

InChI

0 references

1 reference

ChEBI release 2020-09-01

CAS Registry Number

137281-23-3

1 reference

https://commonchemistry.cas.org/detail?cas_rn=137281-23-3

8 April 2021

0 references

0 references

1 reference

ChEBI ID

63616

mapping relation type

exact match

1 reference

International Chemical Identifier

InChI

InChI=1S/C20H21N5O6/c21-20-24-16-15(18(29)25-20)12(9-22-16)6-3-10-1-4-11(5-2-10)17(28)23-13(19(30)31)7-8-14(26)27/h1-2,4-5,9,13H,3,6-8H2,(H,23,28)(H,26,27)(H,30,31)(H4,21,22,24,25,29)/t13-/m0/s1

0 references

1 reference

8 February 2021

2 references

inferred from InChIKey

209720

2 references

based on heuristic

inferred from InChIKey

HSDB ID

7316

1 reference

Hazardous Substances Data Bank

28 October 2019

PEMETREXED (English)

10 May 2021

2 references

Mapping file of InChIStrings, InChIKeys and DTXSIDs for the EPA CompTox Dashboard

DSSTOX compound identifier

0 references

0 references

0 references

ECHA Substance Infocard ID

100.205.735

1 reference

ECHA Substance Infocard database

ECHA Substance Infocard ID

100.205.735

27 December 2018

(2S)-2-{[4-(2-{2-amino-4-oxo-3H,4H,7H-pyrrolo[2,3-d]pyrimidin-5-yl}ethyl)phenyl]formamido}pentanedioic acid (English)

quotation

CAS no.: 137281-23-3 (English)

1 reference

World Health Organisation international non-proprietary name numeric ID

Pemetrexed (English)

publication date

17 November 2015

7675

0 references

D03.633.100.759.758.399.454.650

0 references

Pemetrexed

0 references

MeSH tree code

0 references

0 references

0 references

0 references

1 reference

2 references

PEMETREXED (English)

19 January 2016

MedlinePlus drug identifier

a607043

0 references

PatientsLikeMe treatment ID

0 references

1 reference